LEE'S PHARM (00950) Receives NMPA Approval for Inrosa

Stock News

Mar 25

It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1163342752"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163342752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163342752?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163342752","market":"sg","top_or_hot":-1,"title":"LEE'S PHARM (00950) Receives NMPA Approval for Inrosa","media":"Stock News","content":"<p>It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEE'S PHARM (00950) Receives NMPA Approval for Inrosa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEE'S PHARM (00950) Receives NMPA Approval for Inrosa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-25 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"","article_id":"1163342752","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163342752","pubTimestamp":1774445903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1587":"次新股","06622":"兆科眼科-B","BK1574":"生物医药B类股","00950":"李氏大药厂","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"李氏药业(00950)Inrosa获NMPA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1,"00950":1},"content_text":"It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}